# The drugmaker posted adjusted earnings of $1.58 per share for the quarter.

*business · news · 2026-04-30 · Reuters*

## Key points

- Bristol Myers' revenue and adjusted earnings beat analyst expectations this quarter, reaching $11.49 billion and $1.58 per share.
- Sales from Bristol Myers' newer cancer medicines, including Breyanzi and Camzyos, offset declines in older drugs like Revlimid.
- Opdivo sales fell 5% to $2.15 billion, with the drop attributed to reduced wholesaler inventory levels.
- Bristol Myers has already achieved $1 billion in cost savings, targeting $2 billion by the end of 2025.
- CEO Chris Boerner disclosed that AI is accelerating drug identification by 50% and reducing clinical development cycle times by 30%.

**Companies:** Bristol Myers
**Countries:** United States, India

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-posts-higher-than-expected-quarterly-profit-blood-thinner-cancer-2026-04-30/)

---

Canonical: https://newsio.io/n/5f04b386-dc06-4271-94e3-96e347c7841e/the-drugmaker-posted-adjusted-earnings-of-1-58-per-share-for-the-quarter-sales-f
Summarized by Newsio from Reuters. https://newsio.io/how-it-works